The Texas A&M University System and XOMA Corporation XOMA, a leader
in the discovery and development of therapeutic antibodies, today announced
that the Texas A&M University System agreed to a non-exclusive license for
XOMA's innovative design of a manufacturing facility. The patented technology
relates to a flexible arrangement of mobile clean rooms (MCRs) within the
manufacturing facility with each MCR providing a portable, self-contained
environment that allows for drug development. The A&M System will use MCRs for
certain government programs at The National Center for Therapeutics
Manufacturing (NCTM) facility, a multidisciplinary workforce education
institution and biopharmaceutical manufacturing center, located at Texas A&M
University in College Station, Texas. Details of the license were not
disclosed.
"Today's announcement is the culmination of years of collaborative work begun
when Texas A&M assembled a small group of world leading experts to solve the
manufacturing challenges essential for biosecurity," said Dr. Brett Giroir,
Executive Vice President and CEO of the Texas A&M Health Science Center. "This
team included Dr. Patrick Scannon and other XOMA experts, who developed
concepts that have now been uniquely implemented by Texas A&M through our
pioneering biomanufacturing facilities, including the Texas A&M Center for
Innovation sponsored by the U.S. Department of Health and Human Services. The
MCR technology is an important component of our vaccine and medical
countermeasure technologies that may be important for responses to Ebola and
other emerging diseases."
"This license validates our flexible manufacturing design as it will be in
practice initially at a well-known educational facility," stated Patrick J.
Scannon, MD, PhD, Founder and Chief Scientific Officer of XOMA. "Mobile clean
rooms have the potential to transform the industry because of their 'plug and
play' design, which offers benefits of easy scalability and reduced clean-out
and set-up times. In addition, they offer the potential to respond to possible
threats in locales where pharmaceutical or biologic manufacturing facilities
are otherwise not available."
The flexible manufacturing facility design allows MCRs to connect easily and
quickly to a central supply of utilities such as air, water, and electricity.
This unique arrangement facilitates flexible design and eliminates change-over
downtime. This translates into significantly reduced capital expenditures,
production costs, and maintenance costs while offering meaningful time
advantages over conventional manufacturing facilities. When MCRs are not in
use, they can be easily moved to cleaning/refurbishing areas and prepared MCRs
can be "plugged in" for manufacturing.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in